公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2018 | Pembrolizumab for the treatment of advanced salivary gland carcinoma | Cohen R.B.; Delord J.-P.; Doi T.; Piha-Paul S.A.; Liu S.V.; Gilbert J.; Algazi A.P.; Damian S.; RUEY-LONG HONG ; Le Tourneau C.; Day D.; Varga A.; Elez E.; Wallmark J.; Saraf S.; Thanigaimani P.; Cheng J.; Keam B. | American Journal of Clinical Oncology: Cancer Clinical Trials | 148 | 119 | |
2017 | Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: Results of the KEYnote-028 study | CHIUN HSU ; Lee S.-H.; Ejadi S.; Even C.; Cohen R.B.; Le Tourneau C.; Mehnert J.M.; Algazi A.; Van Brummelen E.M.J.; Saraf S.; Thanigaimani P.; Cheng J.D.; Hansen A.R. | Journal of Clinical Oncology | 315 | 280 | |
2019 | Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer | Mehnert J.M.; Varga A.; Brose M.S.; Aggarwal R.R.; CHIA-CHI LIN ; Prawira A.; De Braud F.; Tamura K.; Doi T.; Piha-Paul S.A.; Gilbert J.; Saraf S.; Thanigaimani P.; Cheng J.D.; Keam B. | BMC Cancer | 132 | 108 |